Avalo Therapeutics (NASDAQ:AVTX) Stock Rating Upgraded by Wall Street Zen

Avalo Therapeutics (NASDAQ:AVTX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Several other brokerages have also recently weighed in on AVTX. Weiss Ratings raised shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. HC Wainwright lowered shares of Avalo Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, October 23rd. Wedbush decreased their price objective on shares of Avalo Therapeutics from $22.00 to $20.00 and set an “outperform” rating on the stock in a research report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Avalo Therapeutics in a research report on Wednesday, September 16th. Finally, Guggenheim downgraded shares of Avalo Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, October 23rd. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $36.82.

Avalo Therapeutics Stock Performance

Shares of AVTX stock opened at $6.93 on Friday. The company has a market capitalization of $373.67 million, a P/E ratio of -2.75 and a beta of 0.76. Avalo Therapeutics has a fifty-two week low of $6.53 and a fifty-two week high of $24.27. The stock has a 50 day moving average price of $13.48 and a two-hundred day moving average price of $15.84.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.25. As a group, equities analysts predict that Avalo Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Avalo Therapeutics

In other news, CFO Christopher Sullivan sold 12,394 shares of Avalo Therapeutics stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the sale, the chief financial officer owned 39,900 shares of the company’s stock, valued at approximately $651,567. The trade was a 23.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 23,258 shares of company stock worth $395,434. Insiders own 4.46% of the company’s stock.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors have recently bought and sold shares of AVTX. AlphaCentric Advisors LLC purchased a new stake in Avalo Therapeutics in the first quarter worth $174,000. Glenmede Trust Co. NA boosted its holdings in shares of Avalo Therapeutics by 25.8% during the 1st quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock valued at $384,000 after buying an additional 5,280 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics during the 1st quarter valued at $607,000. Sei Investments Co. purchased a new stake in shares of Avalo Therapeutics in the 1st quarter worth about $849,000. Finally, Renaissance Technologies LLC grew its position in shares of Avalo Therapeutics by 556.4% in the 1st quarter. Renaissance Technologies LLC now owns 120,114 shares of the company’s stock worth $1,793,000 after buying an additional 101,814 shares during the period. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.